Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study. Welt, A., Welslau, M., Lüftner, D., Deryal, M., Liersch, R., Sahlmann, J., Houet, L., Potthoff, K., Marschner, N., 2020. Oncol Res Treat 43 (suppl 1)(270), 13–14. Palbociclib in combination with anastrozole or exemestane for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany. Interim results of the INGE-B phase 2 trial. M. Welslau, N. Marschner, U. Söling, C. Brucker, O.J. Stoetzer, J. Meiler, P.Wimberger, S.Dörfel, J.Sahlmann, L.Houet, C.Vannier, K.Potthoff, 2019. Cancer Res February 15 2020 (80)… Weiterlesen Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study. Lüftner, D., Welslau, M., Liersch, R., Deryal, M., Brucker, C., Rauh, J., Welt, A., Zaiss, M., Houet, L., Vannier, C., Potthoff, K., Marschner, N., 2020. Weiterlesen